Abstract: We found no significant difference in the risk of VF, though did observe a trend toward more VF and M184 V mutations among persons initiating MTR.
Method: Among VF patients we examined the frequency of common resistance mutations: K103N, M18
Result: Of these, 25 (69%) had a K103N, 4 (11%) a K65R, 14 (39%) an M184 V/I, and 7 (19%) had a thymidine analog mutation.
Result: While a trend was seen toward an increased likelihood of M184 V mutations in the MTR group (5 out of 7) compared with the STR group (9 out of 29), it did not reach statistical significance.
Discussion: The suggestion of more M184 V mutations in the MTR group is however intriguing and deserves further study.
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
PMID: 28453836
2017
The Journal of infectious diseases
Abstract: Only 1 patient had K65R (0.01%) and 7 had M184V/I (0.1%), despite high use of tenofovir disoproxil fumarate (TDF), emtricitabine, and lamivudine and potential transmission of resistance to these drugs.
Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network.
Abstract: Decreased transmission fitness was demonstrated for twenty-three mutations, including M184V.
HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.
PMID: 28472323
2017
The Journal of antimicrobial chemotherapy
Result: Again, the acquisition of M184V/I was faster for large cluster as compared with small cluster lineages.
Result: Drug dose escalations with lamivudine in large cluster variants were associated with the appearance at week 8 of M184V (isolate 14947) or M184I (isolates 14637, 14997 and 14637).
Result: Dual selections with dolutegravir and lamivudine showed the appearance of resistance in only one large cluster isolate (14947) with the first appearance of R263K at week 8 preceding the acquisition of M184I/V and M184V at weeks 15 and 23, respectively (Figure4d).
Result: Interestingly, culturing HIV-1 isolate 14947 (cluster 185) with dolutegravir led to the rapid selection of variants carrying the R263K mutation, as r
A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011.
Discussion: According to the IAS tables published from 2001 to 2004, the most frequent mutation that we observed for the RT gene-M184V -confers resistance to Zalcitabine, which also appears as the most frequent drug resistance in our analysis (Fig 3).
Discussion: The IAS data also associates M184V with the antiretrovirals Didanosine and Lamivudine, which were the second and third most frequent medications observed for our samples.
Discussion: The predominant RT mutation observed in this study-M184V -is widely considered to be the most critical mutation with respect to resistance to multiple nucleoside and nucleotide analog RT inhibitors (NRTIs).
Treatment Outcomes of Third-line Antiretroviral Regimens in HIV-infected Thai Adolescents.
PMID: 28520611
2017
The Pediatric infectious disease journal
Abstract: Genotypes at time of second-line failure (n = 44) were M184V (77%), >=4 thymidine analogue mutations (25%), non-nucleoside reverse transcriptase inhibitor-resistant associated mutation (RAM) (80%), ETR-RAM score >=4 (14%), any lopinavir-RAM (59%) and >=1 major DRV-RAM (41%).
Virological Suppression and Patterns of Resistance Amongst Patients on Antiretroviral Therapy at 4 Nigerian Military Hospitals.
Abstract: Of the remainder, 10% (3/30) had no nucleoside analogue mutations while 33% (10/30) had only M184V along with non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations (K103N or Y188C).
Use of Proviral DNA to Investigate Virus Resistance Mutations in HIV-infected Zimbabweans.
Abstract: Six-percent (n=6) had at least one HIVDR mutation, comprising NRTI-associated mutations, (M184V, T69D, T69N and V75I); NNRTI-associated mutations (G190A, K103N, V106M, Y181C) and thymidine analogue associated mutations (D67N, K70R, K219Q, L210W, M41L, T215Y).
Result: One (0.97%) of the samples analyzed had only one NRTI mutation (T69N); two of the sa
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Abstract: INTERPRETATION: After viral suppression with boosted protease inhibitor plus NRTI in second-line ART, maintenance therapy with boosted protease inhibitor plus lamivudine was associated with a high rate of success, despite the presence of M184V mutations at first-line treatment failure.
Abstract: Participants for our study were HIV-1 infected with multiple mutations including M184V, at first-line failure, aged 18 years and older, on boosted protease inhibitor plus two nucleoside reverse transcriptase inhibitors (NRTI) for at least 48 weeks with at least 48 weeks follow-up in the 2LADY trial, with two viral load measurements of less than 200 copies per
Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee.
Abstract: However, initial lack of adherence and/or differences in pharmacokinetics led to low plasma drug concentrations, which resulted in transient rebound viremia and the emergence of FTC resistance mutations (M184V/I) identical to those observed in HIV-1 infected humans.
Introduction: Interestingly, this was not the case in Cotton where both M184I (ATG to ATA) and M184V (ATG to GTA) were observed at viral rebound, but M184I remained the predominant mutation.
Introduction: This analysis revealed the emergence of M184V and M184I mutations in the conserved YMDD motif of the viral reverse transcriptase (RT) nine months after the onset of therapy.|mgd
HIV mutation literature information.
PMID: 
2017
Medicine
Browser Board
Co-occurred Entities
Filtrator
ViMRT